Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Capital Expenditures (2023 - 2025)

Compass Therapeutics' Capital Expenditures history spans 3 years, with the latest figure at $7000.0 for Q3 2025.

  • For Q3 2025, Capital Expenditures fell 84.09% year-over-year to $7000.0; the TTM value through Dec 2025 reached $25000.0, down 43.18%, while the annual FY2025 figure was $25000.0, 43.18% down from the prior year.
  • Capital Expenditures for Q3 2025 was $7000.0 at Compass Therapeutics, down from $18000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $44000.0 in Q3 2024 and bottomed at $7000.0 in Q3 2025.
  • The 3-year median for Capital Expenditures is $10500.0 (2023), against an average of $16500.0.
  • The largest annual shift saw Capital Expenditures soared 340.0% in 2024 before it crashed 84.09% in 2025.
  • A 3-year view of Capital Expenditures shows it stood at $9000.0 in 2023, then skyrocketed by 388.89% to $44000.0 in 2024, then plummeted by 84.09% to $7000.0 in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Capital Expenditures are $7000.0 (Q3 2025), $18000.0 (Q1 2025), and $44000.0 (Q3 2024).